Research and Markets (http://www.researchandmarkets.com/research/kbhxp4/male_hypogonadism) has announced the addition of the "Male Hypogonadism - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Male Hypogonadism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Male Hypogonadism and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • Antares Pharma, Inc.
  • BIOCAD
  • Clarus Therapeutics, Inc.
  • Diurnal Limited
  • EndoCeutics, Inc.
  • Ferring International Center S.A.
  • Forendo Pharma Limited
  • Lipocine Inc.
  • M et P Pharma AG
  • Merck & Co., Inc.
  • Mereo Biopharma Group Limited
  • Millennium Pharmaceuticals, Inc.
  • Monosol Rx, LLC
  • Pantarhei Bioscience BV
  • Repros Therapeutics Inc.

Drug Profiles

  • BGS-649
  • corifollitropin alfa
  • enclomiphene
  • fispemifene
  • follitropin alfa
  • Kisspeptin-10
  • Libidua
  • LPCN-1111
  • MSS-722
  • T-2
  • TAK-448
  • TBS-1
  • Testavan
  • testosterone
  • testosterone enanthate
  • testosterone undecanoate

For more information visit http://www.researchandmarkets.com/research/kbhxp4/male_hypogonadism